Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novartis

Behind $2 million per dose gene therapy

How did a drug rooted in government seed money and spurred by grassroots fundraising end up with such a price tag?

Salon

Aliens, sloths and silliness: Super Bowl ads offer laughs, celebs and surprises to win over viewers

Eugene Levy’s trademark eyebrows fly off for Little Caesars

The Independent UK

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Benzinga

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Benzinga

From biopharma to real estate to shipping, top CEOs insist AI is worth the hype

Stop being afraid of newfangled technology, and start letting your kids use it to help them with their homework, said panelists at Fortune Global Forum.

Fortune

'Pure-play' Novartis Raises 2024 Financial Targets

A year after spinning off its generics business to become a "pure-player" developer of innovative medicines, Novartis registered a 15 percent increase in its core net profit to $4.1 billion during the July-September period, from the same quarter last year.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Chart of the Day: Novartis - Take Another Look

The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Barchart

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

International Business Times

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Barchart

US Appeals Court Revives Regeneron Antitrust Lawsuit Against Novartis

U.S. appeals court revives Regeneron's antitrust lawsuit against Novartis, highlighting alleged anticompetitive behavior.

Top News

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

Could new malaria drug give babies a better chance of survival?

Trials are under way for a treatment for newborns and infants, who are often wrongly assumed to have immunity through their mothers

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

We could see thunderstorm asthma in south-eastern Australia this season – here's how to prepare

Victorians have been warned to prepare for the possibility of thunderstorm asthma again this season.

The Guardian - UK

Revealed: drug firms funding UK patient groups that lobby for NHS approval of medicines

Observer investigation shows that majority of Nice drug appraisals involve groups financially linked to maker of pharmaceuticals

The Guardian - UK

Panadol maker plans sweeping job cuts a year after being spun off from GSK

Exclusive: Consumer healthcare firm Haleon to cut hundreds of roles in UK and potentially thousands globally

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Congress ponders whether AI should have the power of the patent

Lawmakers are beginning to consider ways in which artificial intelligence systems are involved in inventive processes like discovery of new drugs, and how the use of such technologies affects what is, and is not, patentable.

Roll Call

Congress ponders whether AI should have the power of the patent - Roll Call

Lawmakers are beginning to consider ways in which artificial intelligence is involved in inventive processes like discovery of new drugs.

The Guardian - UK

Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions

Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment

The Independent UK

Doctor with Stage 4 cancer is refused access to lifesaving treatment on the NHS

Dr Asha Umrawsingh, 50, was first diagnosed with breast cancer in 2010

Fortune

Over dinner in Davos, the CEOs of Novartis, Coca-Cola, and Grab shared what’s worrying them

Highlights from Fortune's dinner in Davos.

Fortune

Coca-Cola and Novartis's CEOs don't care if 'ESG' has become a toxic phrase among some

It's about delivering on corporate missions in a sustainable way, they said at Davos.

StockNews.com

1 Large-Cap Stock You Should Purchase This Week

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.